MTOR and osteosarcoma: In summary, TRIM17 binds to FTO, promoting its ubiquitination and degradation, enhances PDK1 mRNA stability in an m6A-dependent manner, activates the AKT/mTOR signaling axis, and drives osteosarcoma cell clonability and survival potential and invasion, thereby contributing to osteosarcoma progression.